Literature DB >> 30849632

Nanobodies detecting and modulating GPCRs outside in and inside out.

Raimond Heukers1, Timo W M De Groof2, Martine J Smit3.   

Abstract

G protein-coupled receptors (GPCRs), belonging to the largest class of membrane proteins, play a prominent role in many (patho)physiological processes and are, therefore, important drug targets. Although most often targeted by small molecules, these receptors have become interesting targets for antibodies and antibody fragments, especially camelid-derived heavy chain-only antibodies and fragments thereof (nanobodies). The small size and molecular structure of nanobodies allow GPCR-binding and modulation, from both the intracellular and extracellular sides. These molecular features make nanobodies attractive tools to study, modulate, and exploit GPCRs. Besides modulating GPCR activity as monovalent or multivalent constructs, nanobodies can also be functionalized for imaging and therapy. Moreover, GPCR-binding nanobodies have been instrumental in obtaining crystal structures of GPCRs, facilitating structure-based drug discovery. Here, we describe the current status and future perspectives of nanobodies targeting GPCRs intra and extracellularly.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30849632     DOI: 10.1016/j.ceb.2019.01.003

Source DB:  PubMed          Journal:  Curr Opin Cell Biol        ISSN: 0955-0674            Impact factor:   8.382


  14 in total

Review 1.  Exploring cellular biochemistry with nanobodies.

Authors:  Ross W Cheloha; Thibault J Harmand; Charlotte Wijne; Thomas U Schwartz; Hidde L Ploegh
Journal:  J Biol Chem       Date:  2020-08-31       Impact factor: 5.157

2.  Strategies for targeting cell surface proteins using multivalent conjugates and chemical biology.

Authors:  Shivani Sachdev; Chino C Cabalteja; Ross W Cheloha
Journal:  Methods Cell Biol       Date:  2021-07-12       Impact factor: 1.829

3.  ImmunoPET: Concept, Design, and Applications.

Authors:  Weijun Wei; Zachary T Rosenkrans; Jianjun Liu; Gang Huang; Quan-Yong Luo; Weibo Cai
Journal:  Chem Rev       Date:  2020-03-23       Impact factor: 60.622

4.  Rapid identification of highly potent human anti-GPCR antagonist monoclonal antibodies.

Authors:  Martin J Scott; Amanda Jowett; Martin Orecchia; Peter Ertl; Larissa Ouro-Gnao; Julia Ticehurst; David Gower; John Yates; Katie Poulton; Carol Harris; Michael J Mullin; Kathrine J Smith; Alan P Lewis; Nick Barton; Michael L Washburn; Ruud de Wildt
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

5.  Improved GPCR ligands from nanobody tethering.

Authors:  Ross W Cheloha; Fabian A Fischer; Andrew W Woodham; Eileen Daley; Naomi Suminski; Thomas J Gardella; Hidde L Ploegh
Journal:  Nat Commun       Date:  2020-04-29       Impact factor: 14.919

6.  Monitoring Allosteric Interactions with CXCR4 Using NanoBiT Conjugated Nanobodies.

Authors:  Mark Soave; Raimond Heukers; Barrie Kellam; Jeanette Woolard; Martine J Smit; Stephen J Briddon; Stephen J Hill
Journal:  Cell Chem Biol       Date:  2020-06-30       Impact factor: 8.116

7.  Activation of a G protein-coupled receptor through indirect antibody-mediated tethering of ligands.

Authors:  Ross W Cheloha; Fabian A Fischer; Thomas J Gardella; Hidde L Ploegh
Journal:  RSC Chem Biol       Date:  2021-10-11

8.  Allosteric Effect of Nanobody Binding on Ligand-Specific Active States of the β2 Adrenergic Receptor.

Authors:  Yue Chen; Oliver Fleetwood; Sergio Pérez-Conesa; Lucie Delemotte
Journal:  J Chem Inf Model       Date:  2021-11-15       Impact factor: 4.956

9.  Selective targeting of ligand-dependent and -independent signaling by GPCR conformation-specific anti-US28 intrabodies.

Authors:  Timo W M De Groof; Nick D Bergkamp; Raimond Heukers; Truc Giap; Maarten P Bebelman; Richard Goeij-de Haas; Sander R Piersma; Connie R Jimenez; K Christopher Garcia; Hidde L Ploegh; Marco Siderius; Martine J Smit
Journal:  Nat Commun       Date:  2021-07-16       Impact factor: 17.694

10.  Targeting the latent human cytomegalovirus reservoir for T-cell-mediated killing with virus-specific nanobodies.

Authors:  Timo W M De Groof; Elizabeth G Elder; Eleanor Y Lim; Raimond Heukers; Nick D Bergkamp; Ian J Groves; Mark Wills; John H Sinclair; Martine J Smit
Journal:  Nat Commun       Date:  2021-07-21       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.